Journal Watch: evidence that Atorvastatin reduces the risk of stroke and myocardial infarction in patients with type 2 diabetes, but with no evidence of dyslipidaemia.

Gangaidzo, I T

Gangaidzo, I T.

Cent Afr J Med ; 51(11-12): 125-6, 2005.

Article in En | MEDLINE | ID: mdl-17447346

Subject(s)

Anticholesteremic Agents/therapeutic use; Diabetes Mellitus, Type 2/complications; Heptanoic Acids/therapeutic use; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use; Myocardial Infarction/prevention & control; Pyrroles/therapeutic use; Stroke/prevention & control; Anticholesteremic Agents/pharmacology; Atorvastatin; Heptanoic Acids/pharmacology; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology; Myocardial Infarction/etiology; Pyrroles/pharmacology; Risk Factors; Stroke/etiology

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Pyrroles / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Stroke / Diabetes Mellitus, Type 2 / Heptanoic Acids / Anticholesteremic Agents / Myocardial Infarction Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Cent Afr J Med Year: 2005 Document type: Article

Search on Google

Add to My VHL

XML

PubMed Links